SCHEMBL12371522

SCHEMBL12371522

CCCCCCC[C@H](CCI)OC

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ZDHHC7 Q9NXF8 1/20 0.37
PRKD3 O94806 3/20 0.37
PRKCG P05129 3/20 0.37
PRKCB P05771 3/20 0.37
PRKCA P17252 3/20 0.37
PRKCH P24723 3/20 0.37
PRKCI P41743 3/20 0.37
PRKCE Q02156 3/20 0.37
PRKCQ Q04759 3/20 0.37
PRKCZ Q05513 3/20 0.37
PRKCD Q05655 3/20 0.37
PRKD1 Q15139 3/20 0.37
LMNA P02545 1/20 0.37
LPAR6 P43657 3/20 0.36
LPAR1 Q92633 3/20 0.36
LPAR4 Q99677 3/20 0.36
LPAR5 Q9H1C0 3/20 0.36
LPAR2 Q9HBW0 3/20 0.36
LPAR3 Q9UBY5 3/20 0.36
DNM1 Q05193 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11557138 0.98 OPRM1 (0.36) ZDHHC7PRKD3PRKCGPRKCBPRKCA
SCHEMBL30915579 0.89 TSHR (0.44) ZDHHC7PRKD3PRKCGPRKCBPRKCA
SCHEMBL20459264 0.89 TSHR (0.44) ZDHHC7PRKD3PRKCGPRKCBPRKCA
SCHEMBL28995099 0.89 TSHR (0.44) ZDHHC7PRKD3PRKCGPRKCBPRKCA
SCHEMBL18165672 0.89 TSHR (0.44) ZDHHC7PRKD3PRKCGPRKCBPRKCA
SCHEMBL13069532 0.89 TSHR (0.44) ZDHHC7PRKD3PRKCGPRKCBPRKCA
SCHEMBL17676329 0.89 TSHR (0.44) ZDHHC7PRKD3PRKCGPRKCBPRKCA
SCHEMBL13464149 0.89 TSHR (0.44) ZDHHC7PRKD3PRKCGPRKCBPRKCA
SCHEMBL14520047 0.89 TSHR (0.44) ZDHHC7PRKD3PRKCGPRKCBPRKCA
SCHEMBL28820257 0.89 TSHR (0.44) ZDHHC7PRKD3PRKCGPRKCBPRKCA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7994154-B2 Substituted liposaccharides useful in the treatment and prevention of endotoxemia Ersai R&D Management Co., Ltd. (JP) 2011-08-09 US disclosed
US-20100227835-A1 SUBSTITUTED LIPOSACCHARIDES USEFUL IN THE TREATMENT AND PREVENTION OF ENDOTOXEMIA EISAI R&D MANAGEMENT CO., LTD (JP) 2010-09-09 US disclosed
US-7737129-B2 Substituted liposaccharides useful in the treatment and prevention of endotoxemia EISAI R & D MANAGEMENT CO., LTD. (JP) 2010-06-15 US disclosed
US-20080214802-A1 Substituted Liposaccharides Useful in the Treatment and Prevention of Endotoxemia EISAI CO., LTD. (JP) 2008-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214802-A1 Substituted Liposaccharides Useful in the Treatment and Prevention of Endotoxemia LIPG, FUT6, UGCG ZDHHC7 1271/4885PRKD3 3221/4885PRKCG 2702/4885
US-20100227835-A1 SUBSTITUTED LIPOSACCHARIDES USEFUL IN THE TREATMENT AND PREVENTION OF ENDOTOXEMIA LIPG, FUT6, UGCG ZDHHC7 1271/4885PRKD3 3221/4885PRKCG 2702/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.